Skip to main content

Month: August 2024

Net asset value of the EfTEN United Property Fund as of 31.07.2024

The net asset value (NAV) of EfTEN United Property Fund unit was 10.65 euros at the end of July, increasing by 0.2% over the month. If the fund’s investment in the EfTEN Real Estate Fund AS shares is reflected on the basis of its net value, the NAV of EfTEN United Property Fund would be 10.75 euros, increasing by 0,4%. In the fund’s development investment of Uus-Järveküla residential area, a construction contract for the third stage development was signed, which includes the construction of 17 terraced houses. The construction works of the third stage are planned to be completed in the summer of 2025, and the construction price will be approximately 1,500 euros (excl VAT) per sellable square meter. At the completion of the third stage, more than 80% of the final development volume of the entire residential area of ​​Uus-Järveküla...

Continue reading

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma and will evaluate a new route forward. Following an additional internal review of the current data package, in light of recent discussions with the National Medical Products Administration of China (“NMPA”), HUTCHMED has determined that the submission is unlikely to support an approval in China at this time. This supplemental NDA for fruquintinib was based on data from the Phase III FRUTIGA study, which was declared positive due to a statistically...

Continue reading

PlantX Announces Filing of Interim Financial Statements for the Three Months Ended June 30, 2024

VANCOUVER, British Columbia, Aug. 29, 2024 (GLOBE NEWSWIRE) — PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) (“PlantX” or the “Company”), the digital face of the plant-based community, operating a one-stop shop for plant-based products, announces the filing of its unaudited condensed interim consolidated financial statements, associated management’s discussion, and analysis and related officer certifications for the three months period ended June 30, 2024 (the “Q1 Filing”). The Q1 Filing is available under the Company’s SEDAR profile at www.sedar.com. Highlights For the Three Months ended June 30,2024 The gross revenue for the three months ended June 2024, was $ 1,299,761 (June 2023; $2,794,942). The cost of goods sold for the three months ended June 2024, was $ 473,728 (June 2023; $1,687,302). The net...

Continue reading

Richtech Robotics Announces Pricing of Upsized $21 Million Public Offering

LAS VEGAS, Aug. 29, 2024 (GLOBE NEWSWIRE) — Richtech Robotics Inc. (Nasdaq: RR), (“Richtech Robotics” or the “Company”), a Nevada-based provider of AI-driven service robots, today announced the pricing of an upsized public offering of an aggregate of 15,555,557 shares of its Class B common stock (or Class B common stock equivalents in lieu thereof), warrants to purchase up to 15,555,557 shares of Class B common stock (the “Warrants”), at a combined public offering price of $1.35 per share (or per Class B common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance and will expire on the five year anniversary of the initial issuance date. The closing of the offering is expected to occur on or about September 3, 2024,...

Continue reading

Ekso Bionics Announces Pricing of $6.0 Million Underwritten Public Offering

SAN RAFAEL, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 3,100,000 units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the fifth anniversary of the date of issuance (a “Series A Warrant”) and one warrant to purchase one share of common stock at an exercise...

Continue reading

Airship AI Announces Pricing of $8.0 Million Public Offering Priced At-Market According to Nasdaq Rules

REDMOND, Wash., Aug. 29, 2024 (GLOBE NEWSWIRE) — Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today announced the pricing of a public offering priced at-market according to Nasdaq rules of 2,882,883 shares of its common stock and warrants to purchase up to an aggregate of 2,882,883 shares of its common stock at a combined public offering price of $2.775 per share and associated common warrant. Each share of common stock is being sold together with one warrant to purchase one share of common stock. The warrants will have an exercise price of $2.65 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about September...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.